A BILL 
To establish a commission to assess, evaluate, and address 
the dependence of the United States on medications, 
devices, and medical equipment from foreign countries. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Commission on Amer-
4
ica’s Medical Security Act’’. 
5
SEC. 2. NATIONAL ACADEMIES REPORT ON AMERICA’S 
6
MEDICAL SUPPLY SECURITY. 
7
(a) IN GENERAL.—Not later than 60 days after the 
8
date of enactment of this Act, the Secretary of Health and 
9
01:19 Mar 28, 2020
H6282
2 
•HR 6282 IH
Human Services shall enter into an agreement with the 
1
National Academies of Sciences, Engineering, and Medi-
2
cine (referred to in this section as the ‘‘National Acad-
3
emies’’) to examine, and, in a manner that does not com-
4
promise national security, report on, the security of the 
5
United States medical product supply chain. 
6
(b) PURPOSES.—The report developed under this sec-
7
tion shall— 
8
(1) assess and evaluate the dependence of the 
9
United States, including the private commercial sec-
10
tor, States, and the Federal Government, on critical 
11
drugs and devices that are sourced or manufactured 
12
outside of the United States, which may include an 
13
analysis of— 
14
(A) the supply chain of critical drugs and 
15
devices of greatest priority to providing health 
16
care; 
17
(B) any potential public health security or 
18
national security risks associated with reliance 
19
on critical drugs and devices sourced or manu-
20
factured outside of the United States, which 
21
may include previous or existing shortages and 
22
public health emergencies, such as infectious 
23
disease outbreaks, bioterror attacks, and other 
24
public health threats; 
25
01:19 Mar 28, 2020
H6282
3 
•HR 6282 IH
(C) any existing supply chain information 
1
gaps, as applicable; and 
2
(D) potential economic impact of increased 
3
domestic manufacturing; and 
4
(2) provide recommendations, which may in-
5
clude a plan to improve the resiliency of the supply 
6
chain for critical drugs and devices as described in 
7
paragraph 
(1), 
and 
to 
address 
any 
supply 
8
vulnerabilities or potential disruptions of such prod-
9
ucts that would significantly affect or pose a threat 
10
to public health security or national security, as ap-
11
propriate, which may include strategies to— 
12
(A) promote supply chain redundancy and 
13
contingency planning; 
14
(B) encourage domestic manufacturing, in-
15
cluding consideration of economic impacts, if 
16
any; 
17
(C) improve supply chain information 
18
gaps; 
19
(D) improve planning considerations for 
20
medical product supply chain capacity during 
21
public health emergencies; and 
22
(E) promote the accessibility of such drugs 
23
and devices. 
24
01:19 Mar 28, 2020
H6282
4 
•HR 6282 IH
(c) INPUT.—In conducting the study and developing 
1
the report under subsection (b), the National Academies 
2
shall— 
3
(1) consider input from the Department of 
4
Health and Human Services, the Department of 
5
Homeland Security, the Department of Defense, the 
6
Department of Commerce, the Department of State, 
7
the Department of Veterans Affairs, the Department 
8
of Justice, and any other Federal agencies as appro-
9
priate; and 
10
(2) consult with relevant stakeholders, which 
11
may include conducting public meetings and other 
12
forms of engagement, as appropriate, with health 
13
care providers, medical professional societies, State- 
14
based societies, public health experts, State and local 
15
public health departments, State medical boards, pa-
16
tient groups, medical product manufacturers, health 
17
care distributors, wholesalers and group purchasing 
18
organizations, pharmacists, and other entities with 
19
experience in health care and public health, as ap-
20
propriate. 
21
(d) DEFINITIONS.—In this section, the terms ‘‘de-
22
vice’’ and ‘‘drug’’ have the meanings given such terms in 
23
01:19 Mar 28, 2020
H6282
5 
•HR 6282 IH
section 201 of the Federal Food, Drug, and Cosmetic Act 
1
(21 U.S.C. 321). 
2
Æ 
01:19 Mar 28, 2020
H6282
